Please use this identifier to cite or link to this item:
Type: Artigo
Title: Association of the CFH Y402H polymorphism with the 1-year response of exudative AMD to intravitreal Anti-VEGF treatment in the brazilian population
Author: Medina, F. M. C.
Da Motta, A. A. L.
Takahashi, W. Y.
Carricondo, P. C.
Dos Santos Motta, M. M.
Melo, M. B.
Vasconcellos, J. P. C.
Abstract: Evidence of the relationship between the polymorphism of the complement factor H (CFH) gene at position 402 (Y402H) and the response to the treatment of wet AMD is controversial. The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with the CFH Y402H polymorphism in the Brazilian population. Forty-six patients treated for wet AMD with bevacizumab or ranibizumab in a pro re nata regimen were included. The evolution of best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the number of injections over 1 year of follow-up were correlated with CFH genotypes. The analysis of variance for the difference between the BCVA denoted as log MAR (logarithm of the minimum angle of resolution) values showed an improvement at 1 year when compared to baseline (p = 0.039). Profile contrast analysis showed that this difference was significant only in the group without the C allele (p = 0.049), without significance in patients presenting with the risk allele (p = 0.241). CRT showed a mean reduction at 1 year compared to baseline (p < 0.001). Significant differences in the profile contrast test were found in the group without the C allele (p < 0.001) and in patients with the risk allele (p = 0.002). No difference was found in the number of injections among the different groups (p = 0.787). The presence of the risk allele of the Y402H polymorphism in the CFH gene was related to a less favorable evolution over 1 year in this sample of the Brazilian population with exudative AMD who were being treated with anti-VEGF drugs. In agreement with similar previous studies, this study concludes that the CFH risk genotypes may affect the disease response to treatment
Subject: Bevacizumab
Country: Suiça
Editor: Karger
Rights: Fechado
Identifier DOI: 10.1159/000475995
Date Issue: 2019
Appears in Collections:FCM - Artigos e Outros Documentos
CBMEG - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-85021064315.pdf283.98 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.